Is Apollo Hospitals overvalued or undervalued?

As of 8 July 2025, Apollo Hospitals has moved from a fair to an attractive valuation grade, indicating a positive shift in its market positioning. The company is currently considered undervalued based on its strong performance metrics. Notable ratios include a PE ratio of 75.24, an EV to EBITDA of 37.68, and a ROE of 17.61%.
In comparison to its peers, Apollo Hospitals stands out with a PEG ratio of 1.23, while Max Healthcare is deemed very expensive with a PE of 111.7, and Fortis Healthcare is also expensive with a PE of 71. The recent stock performance has outpaced the Sensex, with a 1-year return of 19.65% compared to the Sensex's 4.69%, reinforcing the attractiveness of Apollo Hospitals' valuation.